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Individuals with type 1 diabetes try to manage the risk of exercise-induced hypoglycemia by means of 39 
pre-exercise/pre-meal bolus insulin dose reductions and/or consuming additional carbohydrates 40 
during exercise. Both strategies have proven to be effective in offsetting the occurrence against 41 
hypoglycemia, it is unclear as to which one is more beneficial. Consequently, the aim of this study 42 
was to assess the efficacy of carbohydrate supplementation in comparison to bolus insulin dose 43 
reduction to prevent hypoglycemia during moderate-intensity exercise in individuals with type 1 44 
diabetes. 45 
Methods 46 
This was a retrospective controlled analysis of two independent clinical trials. All participants 47 
performed a continuous moderate-intensity cycle ergometer exercise session for ~45 minutes. Two 48 
different therapy management groups and a control group were compared: Group (A) supplemented 49 
15 – 30 g carbohydrates at a glycemic threshold of 7.0 mmol/L during exercise, group (B) reduced 50 
their individual bolus insulin dose by 50% with their last meal prior to exercise and group (C) 51 
remained as a control.  52 
Results 53 
No hypoglycemic events occurred in group A, which differed to each four events recorded in groups 54 
B (p = 0.02) and C (p = 0.02). 55 
Conclusion 56 
Carbohydrate supplementation was superior to bolus insulin reductions in the prevention of 57 
hypoglycemia during exercise in people with type 1 diabetes.  58 
 59 












Physical exercise has become an important option in the adjuvant therapy and management of type 70 
1 diabetes (T1D) [1]. Due to the specific nature of its pathology, individuals are reliant on exogenous 71 
insulin either via multiple daily insulin injections (MDI) or continuous subcutaneous insulin infusion 72 
(CSII) [2]. In combination with intermittently scanned or continuous glucose monitoring measuring 73 
glucose, the management of T1D has advanced over the last decades. The induced improved 74 
glycemic management induce several benefits such as increased quality of life [3,4] and reduction of 75 
diabetes-specific comorbidities [5,6]. Nevertheless, the management of glycaemia around exercise is 76 
an intricately complex task, especially when considering the guidelines to achieve a blood glucose 77 
(BG) between 7.0 mmol/L to 10.0 mmol/L commencing exercise [7–9]. For most individuals with T1D 78 
the goal is the absolute avoidance of hypoglycemia around exercise. However, especially during 79 
physical exercise, the fear of hypoglycaemia is still understandable since hypoglycaemia can severely 80 
impact autonomic health which remains a major hurdle  to regularly perform physical exercise safely 81 
[10,11].  82 
Studies have introduced concepts to reduce the risk of exercise-induced hypoglycemia. Strategies 83 
include reductions to bolus or basal insulin dose prior to exercise [12–15] and/or threshold-based 84 
carbohydrate (CHO) supplementation during exercise for adults [16] and adolescents with T1D [17]. 85 
It is unclear which of these approaches are most efficacious in avoiding hypoglycemia and reducing 86 
glycemic disturbances during exercise in individuals with T1D. The aim of this analysis was to assess 87 
the efficacy of CHO supplementation versus bolus insulin dose reductions to prevent hypoglycemia 88 
during exercise in individuals with T1D.  89 
 90 
Methods 91 
This retrospective analysis consisted of two clinical trials investigating insulin dose reduction 92 
strategies for moderate-intensity exercise [13,16]. Data from 18 adults with T1D on a stable basal 93 
insulin degludec- (Tresiba®, Novo Nordisk A/S, DEN) and bolus insulin aspart-therapy (Novo Nordisk 94 
A/S, DEN) were included. All procedures in this trial were performed according to Good Clinical 95 
Practice and the Declaration of Helsinki. Participants were divided into three groups, two of which 96 
were tested in a crossover design with a minimum washout period of one week between each 97 
exercise session (groups B and C). The remaining Group A supplemented 15 – 30 g of fluid CHO (72% 98 
glucose and 28% fructose) or glucose gel (67% glucose and 33% fructose) at a glycemic threshold of 99 
7.0 mmol/L during exercise with no pre-exercise bolus insulin reduction. Blood and interstitial 100 
glucose was measured every 7 minutes during the exercise test. If a participant’s BG was close to 101 
reaching the threshold of 7.0 mmol/L (within 1.0 mmol/L), then measurements were repeated at 3-102 
minute intervals. Group A consumed their last carbohydrate-rich meal at least 2 hours prior to the 103 
moderate-intensity exercise session with their regular individual CHO to bolus insulin dose ratio 104 
which consisted of 1 g CHO per kg bodyweight [16]. Group B reduced their regular bolus insulin dose 105 
by 50% one hour prior to the start of exercise with their last meal (1 g CHO per kg bodyweight). 106 
Group C remained as a control group and did not perform a bolus insulin reduction prior to exercise 107 
nor did supplement additional CHO during the moderate-intensity exercise session [13]. However, 108 
they have also consumed their last meal 1 h prior to exercise (1 g CHO per kg bodyweight) with a 109 
regular bolus insulin dose. Prior to each exercise session, all participants in each group were 110 
introduced to the exercise procedure. Group A conducted a 3-minute passive warm-up, a 3-minute 111 
active warm-up at 20W, followed by 49 minutes at the individual target workload, a 3-minute active 112 
cool-down at 20W and 3 minutes of passive cool-down. Group B and C had very similar exercise 113 
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procedures: a 3-minute passive warm-up, a 3-minute active warm-up at 20W, followed by 42 114 
minutes at target workload and 3 minutes of passive cool-down. 115 
The maximum potential test duration for group A was 49 minutes, whereas group B and C had a 116 
maximum potential test duration of 42 minutes. The test duration at moderate-intensity for each 117 
group were due to the set-up of the previous trials according to the predetermined main outcome 118 
[13,16]. Tests were terminated prematurely in all groups if participants reached hypoglycemia (BG 119 
concentration ≤3.9 mmol/L).  120 
At the beginning of each clinical trial, participants performed a cardio-pulmonary exercise test until 121 
volitional exhaustion to determine the individualized intensity for the moderate-intensity exercise 122 
sessions. The intensity was defined as the power (W) at the midpoint between the individual first 123 
(LTP1) and second (LTP2) lactate turn points [18]. During the moderate-intensity exercise sessions, 124 
capillary BG samples from fingertip were taken every 6 – 7 minutes for safety reasons. Decisions for 125 
treatment were made according to capillary BG measurements measured via the glucometer which is 126 
integrated in the reader of the FreeStyle Libre 1 in all groups. Capillary BG samples from the earlobe 127 
(Biosen C-Line system EKF Diagnostic, GER) were taken as a confirmatory glucose measurement.. In 128 
addition, all participants wore an intermittently scanned glucose monitoring (isCGM) (Freestyle® 1, 129 
Abbott Diabetes Care Inc, USA) system, which provided interstitial based glycemic responses during 130 
the exercise sessions. 131 
Numbers of hypoglycemic episodes were counted. Furthermore, data were stratified for the time 132 
spent in glycemic ranges based on BG during exercise defined as: hypoglycemia (≤3.9 mmol/L), 133 
euglycemia (>3.9 – 10 mmol/L) and hyperglycemia (>10 mmol/L). Data were tested for normal 134 
distribution via Shapiro-Wilk test and then compared via student’s t-test, one-way ANOVA or Kruskal-135 
Wallis test with p ≤ 0.05. If applicable, Tukey’s multiple comparison test was applied (post-hoc). Data 136 
are expressed as means (SD) or median [interquartile range] if applicable. All statistical procedures 137 
were conducted via Prism version 7 (GraphPad, San Jose, USA). 138 
 139 
Results 140 
All participants were on multiple daily injection therapy. Participant’s characteristics for group A 141 
were: n = 9, 5 males, age 32.1 ± 9 years, diabetes duration 19 ± 11 years, HbA1c 55 ± 7 mmol/mol 142 
(7.2 ± 0.6% ) and BMI 25.5 ± 3.8 kg/m
2
. Group B and C included the same participants, who 143 
performed the study related exercise sessions in a cross-over design: n = 9, 6 males, age 32.8 ± 10 144 
years, diabetes duration 14 ± 9 years, HbA1c 56 ± 15 mmol/mol (7.3 ± 1.4% ) and BMI 25.9 ± 3.1 145 
kg/m
2
. Inclusion of participants was conducted following matching for age (p = 0.88), diabetes 146 
duration (p = 0.46), HbA1c (p = 0.94) and BMI (p = 0.79).  147 
The number of hypoglycemic events was significantly higher in group B compared to group A (p = 148 
0.02) as well as in group C compared to A (p = 0.02). There were no differences between groups B 149 
and C (Table 1). BG levels prior to the start of exercise were similar between groups (A; 9.9 ± 2.2 150 
mmol/L vs. B; 10.1 ± 2.4 mmol/L vs. C; 10.1 ± 3.5 mmol/L) (p = 0.98). The median BG concentration 151 
during exercise was lower in group C (5.6 [4.2 – 8.6] mmol/L) compared to A (7.6 [6.1 – 9.8]) (p = 152 
0.01) with no significant difference to group B (7.5 ± 2.9 mmol/L) (p = 0.36). Acute post-exercise BG 153 
taken at rest directly after exercise was similar between all groups (A, 7.7 [7.3 – 8.7] mmol/L vs. B; 154 
7.5 ± 2.0 mmol/L vs. C; 6.8 ± 5.9 mmol/L) (p = 0.25). The nadir glucose between group B (4.1 [3.4 - 155 





Table 1 – Efficacy of different glycemic management concepts during exercise in type 1 diabetes 159 
 
A B C p-value 
Number of Events Hypoglycemia 0/9*
 4/9* 4/9 0.05 
Time Hypoglycemia (min) 0
 0 [0 – 9] 12 [0 – 12] 0.01 
Time Euglycemia (min) 49 [28 – 49] 30 [12 – 36] 23 ± 12.2 0.10 
Time Hyperglycemia (min) 0 [0 – 21] 6 [0 – 9] 0 [0 – 6] 0.41 
Time Hypoglycemia (%) 0
 0 [0 – 27] 22 ± 18 0.01 
Time Euglycemia (%) 100 [57 – 100] 71 [47 – 86] 62 ± 27 0.37 
Time Hyperglycemia (%) 0 [0 – 43] 14 [0 – 21.5] 0 [0 – 14.5] 0.43 
Participants consumed CHO (n) 7/9 0/9 0/9 
 Time until reaching hypoglycemia (min) - 33 ± 11.5 31.5 ± 9 0.83 
CHO consumed per participant (g) 20.8 ± 6.7 - - 
 N Total CHO treatments  14 - -  
Abbreviations: A Consumed carbohydrates during exercise at a predefined glucose threshold of 7.0 mmol/L; B: 160 
Reduced individual bolus insulin dose by 50% prior to exercise; C: No carbohydrates were consumed or bolus 161 
insulin reductions prior to exercise. min: Minutes; g: Gram; n: numbers; CHO: carbohydrates. p-value: Results 162 
of ANOVA. * indicates statistically significant difference between group A and B (p ≤ 0.05).  indicates 163 
statistically significant difference between group A and C (p ≤ 0.05) * indicate statistical difference 164 
following post-hoc testing 165 
 166 
Discussion 167 
Since adjustments of bolus insulin dose or basal rate need to be performed 60 to 90 min prior to the 168 
start of exercise, pre-exercise bolus insulin dose reductions might obstruct spontaneous exercise 169 
[8,19,20]. Furthermore, our data indicate that this therapy strategy may still lead to hypoglycemia 170 
during exercise. Our results demonstrated that CHO supplementation during moderate-intensity 171 
exercise was superior to bolus insulin dose reductions to prevent hypoglycemia. Therefore, glycemic 172 
threshold-based CHO supplementation might be a more prudent approach for reducing the risk of 173 
exercise-induced dysglycemia in individuals with T1D. We also found that the time spent in 174 
euglycemia (%) during exercise tended to be higher in the CHO group compared to the other groups 175 
(p = 0.37). Indeed, the relative time in euglycemia for the CHO group was 100% [57-100] in 176 
comparison to 71% [47-86] in the group that performed a bolus insulin dose reduction and to 62 ± 177 
27% in the control group that further supports the glycemic threshold-based CHO supplementation 178 
approach for future studies. Hypoglycemia in group B and C occurred almost at the same time (p = 179 
0.83) which is surprising, since a reduction of bolus insulin dose prior to exercise did not show 180 
superior effects compared to a regular bolus insulin dose as shown previously [14]. Especially for 181 
people with T1D starting to engage in physical exercise, shorter exercise duration (~30 min) might 182 
lower the risk of hypoglycemia as seen in the latter stage of an exercise session. However, after 183 
becoming more experienced to physical exercise and its therapy adaptations, longer-duration 184 
physical exercise (~60 min) can be recommended. 185 
Moser et al. have shown that threshold-based CHO supplementation may lead to ~80% time in target 186 
range during moderate-intensity exercise on five consecutive days [16]. Since these results show the 187 
summary of multiple exercise sessions, these are probably more transferable for daily life (90 188 
sessions). This study only showed the effects of basal-insulin dose reductions and not the effects of 189 
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bolus insulin reductions, which are easier to incorporate if unplanned exercise is conducted. 190 
However, in this aforementioned study with 90 exercise sessions, no hypoglycemic event occurred, 191 
which further supports our findings and encourages the use of threshold-based CHO 192 
supplementation during moderate-intensity exercise. 193 
These findings support people with T1D to exercise spontaneously at a moderate-intensity without 194 
additional planning and changes to their insulin therapy. This can ease every-day life for people with 195 
T1D and lower the hurdle to perform exercise safely and more regularly. Another advantage of this 196 
approach is that hyperglycemia, induced via bolus insulin reductions in preparation to exercise would 197 
become a thing of the past. Although the results for time in range, (7.0 – 10.0 mmol/L) (TIR) were not 198 
statistically different between groups, a TIR of 100% in the CHO group represent a valuable approach 199 
that may lead to a more stable glycemic control in physically active people with T1D. 200 
A limitation of this study is its small sample size from two independent trials. Groups were well 201 
matched and the exercise volume was similar between both trials and therefore remain comparable 202 
[13,16]. These findings cannot be necessarily transferred to all types of exercise; hence studies with 203 
larger sample sizes are needed to investigate different types of exercise. It should be mentioned that 204 
bolus insulin dose reductions must not necessarily lead to hypoglycemia, yet people with T1D should 205 
be vigilant during exercise. Corrections/adaptations of individual bolus insulin dosing should be 206 
performed dependent on the individual’s response to exercise and also in response to planned type, 207 
duration and intensity of exercise [8]. Vigorous intensity exercise or resistance exercise prior to 208 
moderate-intensity exercise may also prevent hypoglycemia, yet demand more effort from the 209 
individual planning to conduct aerobic exercise [21]. It must also be mentioned that increased 210 
carbohydrate intake during moderate-intensity exercise may reduce its beneficial effects in regard to 211 
weight management. However, research by Pinsker et al. have shown that carbohydrate 212 
consumption still remains a necessity since it is the most commonly used option around exercise in 213 
individuals with T1D, which can also be combined with the application of an individualized algorithm 214 
by Francescato et al. to avoid glycemic imbalances induced by exercise [22,23]. 215 
In conclusion, our findings bear potential for the implementation of glycemic-based threshold CHO 216 
supplementation during moderate-intensity exercise in people with T1D. These data provide 217 
compelling evidence for long-term studies to investigate changes in glycemic control assessed by 218 
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